A comprehensive algorithm for determining whether a run‐in strategy will be a cost‐effective design modification in a randomized clinical trial

Kenneth B. Schechtman, Mae E. Gordon

Type: Review

Publication Date: 1993-01-30

Citations: 30

DOI: https://doi.org/10.1002/sim.4780120204

View Publication

Locations

PubMed - View
Statistics in Medicine - View

Similar Works

Action	Title	Year	Authors
+	The use of a run‐in to enhance compliance	1990	janet M. Lang
+	Intent-to-Randomize Corrections for Missing Data Resulting from Run-In Selection Bias in Clinical Trials for Chronic Conditions	2011	Vance W. Berger Behrang Vali
+	Recruitment Costs for a Randomized Clinical Trial	2017	Jeffrey J. Walline Lisa A. Jones‐Jordan Kimberly J. Shaw Jill A Myers Laura Cardenas Alex Nixon David A. Berntsen Donald O. Mutti
+	Run‐In Period	2007	Vance W. Berger Valerie Durkalski
+	Run‐In Period	2014	Vance W. Berger Valerie Durkalski
+	Run-in Periods in Randomized Trials	1998	Ariel Pablos-Méndez R. Graham Barr Steven Shea
+	A Cost-Benefit Approach to the Amount of Experimentation in Clinical Trials	2006	Hamid Pezeshk John Gittins
+ PDF Chat	Application and impact of run-in studies	2018	Michael Fralick Jerry Avorn Jessica M. Franklin Abdurrahman Abdurrob Aaron S. Kesselheim
+ PDF Chat	A class of computational methods to reduce selection bias when designing Phase 3 clinical trials	2024	Tianyu Zhan
+	Planning a clinical trial with allowance for cost and patient recruitment rate	1984	Mohamed Moussa
+	A Bayesian cost-benefit approach to sample size determination and evaluation in clinical trials	2011	Takashi Kikuchi
+	A Class of Computational Methods to Reduce Selection Bias when Designing Phase 3 Clinical Trials	2023	Tianyu Zhan
+	A general inefficacy interim monitoring rule for randomized clinical trials	2010	Boris Freidlin Edward L. Korn Robert J. Gray
+	CLINICAL TRIALS A Place for Randomization in the Interval Between the End of Recruitment and Availability of Results	2000	Richard Lilford D Braunholtz Sarah Edwards
+	Optimizing Trial Design	2009	Cyrus R. Mehta Ping Gao Deepak L. Bhatt Robert A. Harrington Simona Skerjanec James H. Ware
+ PDF Chat	A roadmap to using randomization in clinical trials	2021	Vance W. Berger Louis Bour Kerstine Carter Jonathan Chipman Colin Everett N Heussen Catherine Hewitt R.-D Hilgers Yuqun Luo Jone Renteria
+ PDF Chat	A roadmap to using randomization in clinical trials	2021	Vance W. Berger Louis Bour Kerstine Carter Jonathan Chipman Colin Everett N Heussen Catherine Hewitt R.-D Hilgers Yuqun Luo Jone Renteria
+ PDF Chat	AN OVERVIEW OF RANDOMIZATION IN CLINICAL TRIALS	2020	Javed Ali Khan Pathan Jamal Khan
+	Choosing inclusion criteria that minimize the time and cost of clinical trials	2014	Charles F. Babbs
+	Run-in Periods in Randomized Clinical Trials	2017	Kenneth B. Schechtman

Works That Cite This (17)

Action	Title	Year	Authors
+	Quantitative appraisal of trial methods in reviews: an investigation of antipsychotic drug effects in dementia	2021	Tessa A. Hulshof
+ PDF Chat	Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study	2020	David Collister Jennifer C. Rodrigues Lawrence Mbuagbaw P.J. Devereaux Gordon Guyatt William G. Herrington Michael Walsh
+ PDF Chat	Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology	2007	Kevin J. Carroll
+	Allocating Treatments to Patients in Clinical Trials	2007	Stephen Senn
+	Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run‐in period increase efficiency?	2008	Chris Frost Michael G. Kenward Nick C. Fox
+ PDF Chat	Placebo Washout in Trials of Antipsychotic Drugs	1996	Jan Volavka Thomas B. Cooper Eugene Laska Morris Meisner
+	Run-in Periods in Randomized Trials	1998	Ariel Pablos-Méndez R. Graham Barr Steven Shea
+	Run‐In Period	2014	Vance W. Berger Valerie Durkalski
+	Direct effect on validity of response run-in selection in clinical trials	2003	Vance W. Berger Azadeh Rezvani Vanessa A Makarewicz
+ PDF Chat	Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations	2014	Jennifer S. Gewandter Robert H. Dworkin Dennis C. Turk Michael P. McDermott Ralf Baron Marc R. Gastonguay Ian Gilron Nathaniel P. Katz Cyrus R. Mehta Srinivasa N. Raja

Works Cited by This (9)

Action	Title	Year	Authors
+	The run-in period in clinical trials	1990	Erica Brittain Janet Wittes
+	Estimating the effect of the run‐in on the power of the physicians' health study	1991	janet M. Lang Julie E. Buring Bernard Rosner Nancy R. Cook Charles H. Hennekens
+	Value of a run-in period in a drug trial during pregnancy	1990	William C. Blackwelder Betty K. Hastings Molly L.F. Lee Maria Deloria Knoll
+	Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification	1986	John M. Lachin Mary A. Foulkes
+	Planning the size of a cohort study in the presence of both losses to follow-up and non-compliance	1980	Mari Palta Richard McHugh
+	The effect of partial noncompliance on the power of a clinical trial	1990	Laurence S. Freedman
+ PDF Chat	The determination of sample size in treatment-control comparisons for chronic disease studies in which drop-out or non-adherence is a problem	1967	M. Anthony Schork Richard D. Remington
+	Evaluation and training of medication adherence counselors in a clinical trial: Application of a skill inventory to video-recorded interviews	1981	Michael L. Russell William Insull
+	The use of a run‐in to enhance compliance	1990	janet M. Lang